Comparative evaluation of lateral flow assays to diagnose chronic Trypanosoma cruzi infection in Bolivia.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 23 06 2023
accepted: 20 02 2024
revised: 14 03 2024
medline: 18 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

Bolivia has the highest incidence of Chagas disease (CD) worldwide. Caused by the parasite Trypanasoma cruzi, CD is generally a chronic condition. Diagnosis is logistically and financially challenging, requiring at least two different laboratory-based serological tests. Many CD cases are missed; in Bolivia it is estimated just 6% of individuals chronically infected with T. cruzi get diagnosed. Achieving control on the way to elimination of CD requires a radical simplification of the current CD testing pathways, to overcome the barriers to accessing CD treatment. We aimed to generate unbiased performance data of lateral flow assays (LFAs) for T. cruzi infection in Bolivia, to evaluate their usefulness for improving T. cruzi diagnosis rates in a precise and efficient manner. This retrospective, laboratory-based, diagnostic evaluation study sought to estimate the sensitivity/specificity of 10 commercially available LFAs for T. cruzi, using the current CD diagnostic algorithm employed in Bolivia as the reference test method. All tests were blinded at the study site and performed by three operators. In total, 470 serum samples were tested, including 221 and 249 characterized as CD-positive/-negative, respectively. The LFAs were scored according to their relative importance using a decision-tree-based algorithm, with the mean decrease in Gini index as the scoring metric. The estimates of sensitivities ranged from 62.2-97.7% (95% confidence interval (CI) lower bound 55.0-94.7%); for specificities the range was 78.6-100% (95% CI lower bound 72.0-97.5%); 5/10 and 6/10 tests had sensitivity >90% and specificity >95%, respectively. Four LFAs showed high values of both sensitivity (93-95%) and specificity (97-99%). The agreement between 6 LFAs and the reference tests was almost perfect (Kappa 0.83-0.94). Most LFAs evaluated thus showed performances comparable with current laboratory-based diagnostic methods.

Identifiants

pubmed: 38437237
doi: 10.1371/journal.pntd.0012016
pii: PNTD-D-23-00789
pmc: PMC10939271
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0012016

Informations de copyright

Copyright: © 2024 López et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Am J Trop Med Hyg. 2016 May 4;94(5):1034-9
pubmed: 26976886
Acta Trop. 2010 Jul-Aug;115(1-2):5-13
pubmed: 20382097
PLoS Negl Trop Dis. 2019 May 31;13(5):e0007271
pubmed: 31150377
PLoS Negl Trop Dis. 2016 Aug 29;10(8):e0004792
pubmed: 27571035
Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43
pubmed: 25671846
Infect Genet Evol. 2011 Oct;11(7):1752-60
pubmed: 21801854
J Clin Microbiol. 2021 Nov 18;59(12):e0106221
pubmed: 34469183
PLoS Negl Trop Dis. 2019 Dec 19;13(12):e0007877
pubmed: 31856247
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
BMJ Open. 2021 Oct 29;11(10):e047825
pubmed: 34716159
Parasitol Int. 2017 Apr;66(2):83-88
pubmed: 27940065
Diagn Microbiol Infect Dis. 2003 Aug;46(4):265-71
pubmed: 12944018
Nat Rev Microbiol. 2010 Dec;8(12 Suppl):S17-29
pubmed: 21548184
PLoS Negl Trop Dis. 2023 Aug 22;17(8):e0011547
pubmed: 37607214
PLoS Negl Trop Dis. 2017 Apr 3;11(4):e0005501
pubmed: 28369081

Auteurs

Ronald López (R)

Instituto Nacional de Laboratorios de Salud (INLASA), La Paz, Bolivia.

Andrea García (A)

Instituto Nacional de Laboratorios de Salud (INLASA), La Paz, Bolivia.

José Jorge Chura Aruni (JJ)

Instituto Nacional de Laboratorios de Salud (INLASA), La Paz, Bolivia.

Victor Balboa (V)

Instituto Nacional de Laboratorios de Salud (INLASA), La Paz, Bolivia.

Andrea Rodríguez (A)

Instituto Nacional de Laboratorios de Salud (INLASA), La Paz, Bolivia.

Berra Erkosar (B)

FIND, Campus Biotech, Chemin des Mines 9, Geneva, Switzerland.

Aurélie Kamoun (A)

FIND, Campus Biotech, Chemin des Mines 9, Geneva, Switzerland.

Marcelo Rodriguez (M)

FIND, Campus Biotech, Chemin des Mines 9, Geneva, Switzerland.

Evelin Fortun (E)

Instituto Nacional de Laboratorios de Salud (INLASA), La Paz, Bolivia.

Laura C Bohorquez (LC)

FIND, Campus Biotech, Chemin des Mines 9, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH